Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8683356 | 0.85 | SMN1; SMN2 (0.51) | KDM1ASMN1; SMN2TDP1LMNACYP1A2 | |
| SCHEMBL8683353 | 0.85 | SMN1; SMN2 (0.51) | KDM1ASMN1; SMN2TDP1LMNACYP1A2 | |
| SCHEMBL5034472 | 0.85 | SMN1; SMN2 (0.51) | SMN1; SMN2TDP1LMNACYP1A2CYP2D6 | |
| SCHEMBL11595834 | 0.85 | CYP1A2 (0.56) | SMN1; SMN2TDP1LMNACYP1A2CYP2D6 | |
| SCHEMBL21164629 | 0.83 | CYP1A2 (0.58) | SMN1; SMN2TDP1LMNACYP1A2CYP2D6 | |
| SCHEMBL13499940 | 0.83 | NPSR1 (0.57) | KDM1ASMN1; SMN2LMNACYP1A2HPGD | |
| SCHEMBL325648 | 0.83 | SCN4A (0.60) | KDM1ASMN1; SMN2TDP1LMNACYP1A2 | |
| SCHEMBL11592951 | 0.82 | LMNA (0.57) | SMN1; SMN2TDP1LMNACYP1A2CYP2D6 | |
| SCHEMBL5880864 | 0.81 | TSHR (0.57) | SMN1; SMN2TDP1LMNATSHRHPGD | |
| SCHEMBL3722461 | 0.81 | LMNA (0.50) | KDM1ASMN1; SMN2TDP1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365493-A1 | COMPOUNDS AND METHODS | DemAgtech Pty Ltd (AU) | 2023-11-16 | — | — | US | disclosed |
| US-20230365493-A1 | COMPOUNDS AND METHODS | DemAgtech Pty Ltd (AU) | 2023-11-16 | — | — | US | disclosed |
| WO-2023168484-A1 | \"COMPOUNDS AND METHODS\ | DemAgtech Pty Ltd (AU) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023092188-A1 | \"COMPOUNDS AND METHODS\ | DemAgtech Pty Ltd (AU) | 2023-06-01 | — | — | WO | disclosed |
| US-11229649-B2 | Methods for treating cryptosporidiosis using triazolopyridazines | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190343837-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2019-11-14 | — | — | US | disclosed |
| US-10363254-B2 | Methods for treating cryptosporidiosis using triazolopyridazines | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180064711-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2018-03-08 | — | — | US | disclosed |
| US-20180064711-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2018-03-08 | — | — | US | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | BAYER CROPSCIENCE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229649-B2 | Methods for treating cryptosporidiosis using triazolopyridazines | CLPP, SI, SAMHD1 | KDM1A 2609/4885SMN1; SMN2 3965/4885TDP1 1472/4885 |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | DHPS, FDPS, DPYD | KDM1A 2876/4885SMN1; SMN2 3727/4885TDP1 1983/4885 |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | KDM1A 4312/4885SMN1; SMN2 541/4885TDP1 1815/4885 |
| US-20190343837-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | CLPP, SI, SAMHD1 | KDM1A 2609/4885SMN1; SMN2 3965/4885TDP1 1472/4885 |
| US-20180064711-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | CLPP, SI, SAMHD1 | KDM1A 2609/4885SMN1; SMN2 3965/4885TDP1 1472/4885 |
| US-10363254-B2 | Methods for treating cryptosporidiosis using triazolopyridazines | CLPP, SI, SAMHD1 | KDM1A 2609/4885SMN1; SMN2 3965/4885TDP1 1472/4885 |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | DHPS, FDPS, DPYD | KDM1A 2876/4885SMN1; SMN2 3727/4885TDP1 1983/4885 |
| US-20230365493-A1 | COMPOUNDS AND METHODS | DDT, CYP19A1, CYP1A1 | KDM1A 397/4885SMN1; SMN2 3554/4885TDP1 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.